<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006048</article-id><article-id pub-id-type="pmc">PMC11859796</article-id><article-id pub-id-type="doi">10.3390/ph18020235</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00235</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Predictive Value of <italic toggle="yes">STC2</italic> Gene Expression in Chemotherapy Response in Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz</surname><given-names>Juan P.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="c1-pharmaceuticals-18-00235" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-6701-7603</contrib-id><name><surname>Lampe-Huenul</surname><given-names>Nicol&#x000e1;s</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Pfeffer</surname><given-names>Lawrence Marc</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Desai</surname><given-names>Dhimant</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00235">Laboratorio de Bioqu&#x000ed;mica, Departamento de Qu&#x000ed;mica, Facultad de Ciencias, Universidad de Tarapac&#x000e1;, Arica 1000007, Chile</aff><author-notes><corresp id="c1-pharmaceuticals-18-00235"><label>*</label>Correspondence: <email>jpmunozb@academicos.uta.cl</email>; Tel.: +56-582386199</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>235</elocation-id><history><date date-type="received"><day>25</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>06</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Breast cancer is the most commonly diagnosed cancer among women, and resistance to chemotherapy presents a significant challenge in its treatment. Stanniocalcin-2 (STC2), a glycoprotein involved in calcium homeostasis and cellular stress responses, is frequently overexpressed in various human cancers. Despite its critical role in cellular adaptation to stress, the potential of <italic toggle="yes">STC2</italic> as a biomarker for predicting chemotherapy response has not been evaluated. This study aimed to assess the potential of <italic toggle="yes">STC2</italic> as a predictive biomarker of response to chemotherapy in breast cancer. <bold>Methods</bold>: We utilized publicly available databases to characterize <italic toggle="yes">STC2</italic> expression in breast cancer patients and its role in predicting relapse-free survival (RFS). Moreover, we evaluated the treatment responses of patients subjected to chemotherapy, correlating their outcomes with <italic toggle="yes">STC2</italic> expression levels to determine its potential as a predictive biomarker. Finally, we evaluated the <italic toggle="yes">STC2</italic> expression levels in breast cancer cell lines following exposure to doxorubicin (Dox), the primary anthracycline used in chemotherapy, and they were contrasted with the publicly available dataset. <bold>Results</bold>: The analysis showed that <italic toggle="yes">STC2</italic> is significantly overexpressed in luminal A breast cancer, where it is linked to genetic amplifications. High <italic toggle="yes">STC2</italic> expression was associated with improved RFS in ER-positive patients but correlated with worse outcomes in ER-negative cases. Furthermore, in grade II ER-positive patients, higher STC2 expression is linked to better chemotherapy response, while in grade II ER-negative patients, it was associated with poorer response. Finally, <italic toggle="yes">STC2</italic> downregulation was observed in response to Dox treatment. <bold>Conclusions</bold>: These findings suggest that <italic toggle="yes">STC2</italic> expression serves as a predictive biomarker for chemotherapy response in grade II breast cancer patients.</p></abstract><kwd-group><kwd>stanniocalcin-2 (STC2)</kwd><kwd>breast cancer</kwd><kwd>doxorubicin</kwd><kwd>chemotherapy resistance</kwd><kwd>predictive biomarker</kwd><kwd>cancer prognosis</kwd></kwd-group><funding-group><award-group><funding-source>FONDECYT</funding-source><award-id>11231072</award-id></award-group><award-group><funding-source>UTA MAYOR</funding-source><award-id>4765-24</award-id></award-group><funding-statement>This study was supported by FONDECYT grant 11231072 (to J.P.M.) and UTA MAYOR grant 4765-24 (to J.P.M).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00235"><title>1. Introduction</title><p>Stanniocalcin-2 (STC2) is a member of a conserved family of secreted glycoprotein hormones originally identified in fish, where it plays a role in regulating calcium levels [<xref rid="B1-pharmaceuticals-18-00235" ref-type="bibr">1</xref>]. In humans, the <italic toggle="yes">STC2</italic> gene is located on chromosome 5q35.1, and it is widely expressed in various tissues, including the breast, muscle, heart, and pancreas [<xref rid="B2-pharmaceuticals-18-00235" ref-type="bibr">2</xref>]. <italic toggle="yes">STC2</italic> has been shown to participate in numerous physiological processes, such as calcium and phosphate homeostasis, cellular stress response, cellular metabolism, inflammation, and antioxidative function [<xref rid="B3-pharmaceuticals-18-00235" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00235" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-18-00235" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-18-00235" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00235" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-18-00235" ref-type="bibr">8</xref>].</p><p>Recent studies have highlighted <italic toggle="yes">STC2</italic> as a gene of interest in cancer biology due to its upregulation in a wide range of human cancers, including breast cancer, esophageal squamous-cell carcinoma, hepatocellular carcinoma, colorectal cancer, gastric cancer, renal cell carcinoma, and prostate cancer [<xref rid="B9-pharmaceuticals-18-00235" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-18-00235" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-18-00235" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-18-00235" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-18-00235" ref-type="bibr">13</xref>]. Interestingly, the expression of <italic toggle="yes">STC2</italic> is closely associated with tumor progression and metastasis [<xref rid="B14-pharmaceuticals-18-00235" ref-type="bibr">14</xref>]. In breast cancer specifically, <italic toggle="yes">STC2</italic> is frequently co-expressed with the estrogen receptor (ER) [<xref rid="B15-pharmaceuticals-18-00235" ref-type="bibr">15</xref>], a key driver of tumor growth expressed in about 80% of breast cancer cases [<xref rid="B16-pharmaceuticals-18-00235" ref-type="bibr">16</xref>]. In fact, <italic toggle="yes">STC2</italic> expression is positively regulated by estrogen signaling, and higher levels of <italic toggle="yes">STC2</italic> have been linked to better disease-free survival rates in ER-positive breast cancer patients. However, this correlation does not hold true for hormone receptor-negative patients [<xref rid="B17-pharmaceuticals-18-00235" ref-type="bibr">17</xref>]. Moreover, recent studies have shown that STC2 suppresses the migration and invasion of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition (EMT) and promoting cell apoptosis [<xref rid="B18-pharmaceuticals-18-00235" ref-type="bibr">18</xref>].</p><p>One of the primary challenges in breast cancer treatment is overcoming resistance to chemotherapeutic compounds, particularly anthracyclines and taxanes [<xref rid="B19-pharmaceuticals-18-00235" ref-type="bibr">19</xref>]. Doxorubicin (Dox) is an anthracycline-class anticancer agent widely utilized in the treatment of various human malignancies, including leukemias, neuroblastoma, bone sarcomas, ovarian cancer, thyroid cancer, gastric cancer, lymphoma, lung cancer, and breast cancer [<xref rid="B20-pharmaceuticals-18-00235" ref-type="bibr">20</xref>]. Dox works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cell death [<xref rid="B21-pharmaceuticals-18-00235" ref-type="bibr">21</xref>]. However, many patients develop resistance, which limits the effectiveness of the drug and leads to cancer recurrence [<xref rid="B22-pharmaceuticals-18-00235" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00235" ref-type="bibr">23</xref>].</p><p>Under stress conditions, including endoplasmic reticulum stress, hypoxia, and nutrient deprivation, <italic toggle="yes">STC2</italic> expression is significantly upregulated, promoting the maintenance of redox homeostasis, resistance to apoptosis, and cell survival [<xref rid="B7-pharmaceuticals-18-00235" ref-type="bibr">7</xref>,<xref rid="B24-pharmaceuticals-18-00235" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-18-00235" ref-type="bibr">25</xref>]. These stress-related functions of <italic toggle="yes">STC2</italic> are especially pertinent within the tumor microenvironment, where cancer cells frequently encounter adverse conditions that foster the selection of more aggressive and therapy-resistant cell populations [<xref rid="B26-pharmaceuticals-18-00235" ref-type="bibr">26</xref>]. Despite its critical role in cellular adaptation to stress, the potential of <italic toggle="yes">STC2</italic> as a biomarker for predicting chemotherapy response has not yet been evaluated.</p><p>Given the critical role of <italic toggle="yes">STC2</italic> in the stress response, the aim of this work is to evaluate the potential of <italic toggle="yes">STC2</italic> as a predictive biomarker of response to chemotherapeutic agents in breast cancer. To this end, we evaluated <italic toggle="yes">STC2</italic> expression patterns from public databases and their impact on treatment outcomes. The results shown here provide evidence that <italic toggle="yes">STC2</italic> gene expression could serve as a predictive biomarker for chemotherapy response in breast cancer patients.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00235"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-18-00235"><title>2.1. STC2 Is Overexpressed in Luminal A Breast Cancer</title><p>To assess the expression of the <italic toggle="yes">STC2</italic> gene across multiple cancer types, we first analyzed <italic toggle="yes">STC2</italic> mRNA expression levels in tumor and normal tissues using the TNM platform, which integrates data from Gene Expression Omnibus (GEO), Genotype-Tissue Expression (GTex), The Cancer Genome Atlas (TCGA), and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) databases. As shown in <xref rid="app1-pharmaceuticals-18-00235" ref-type="app">Figure S1</xref>, <italic toggle="yes">STC2</italic> is overexpressed across a range of cancers, including bladder, colon, esophagus, liver, lung, ovary, pancreas, prostate, rectum, renal cell carcinoma, skin, testis, thyroid, and uterus. Notably, <italic toggle="yes">STC2</italic> mRNA in breast cancer is significantly elevated compared to their corresponding normal tissues (<italic toggle="yes">p</italic> = 1.44 &#x000d7; 10<sup>&#x02212;2</sup>, <xref rid="pharmaceuticals-18-00235-f001" ref-type="fig">Figure 1</xref>A). The analysis revealed that all tumors have <italic toggle="yes">STC2</italic> expression above the minimum cutoff. The percentage of tumors exceeding higher cutoffs decreases progressively, with 74.3% above Q1, 65.7% above the median, 34.3% above Q3, and only 1.4% above the maximum cutoff (<xref rid="app1-pharmaceuticals-18-00235" ref-type="app">Figure S2</xref>). This pattern suggests a widespread but variable overexpression of <italic toggle="yes">STC2</italic> in breast cancer cases. Interestingly, <italic toggle="yes">STC2</italic> overexpression in breast cancer is strongly associated with genetic alterations, such as amplifications and gains, which could explain its overexpression (<xref rid="app1-pharmaceuticals-18-00235" ref-type="app">Figure S3</xref>).</p><p>To further explore the expression patterns of <italic toggle="yes">STC2</italic> across different molecular subtypes of breast cancer, we analyzed its expression using the Gene Expression Profiling Interactive Analysis 2.0 (GEPIA2.0) platform. Our analysis revealed that <italic toggle="yes">STC2</italic> is predominantly overexpressed in the luminal A subtype, while other subtypes exhibit significantly lower or non-significant expression levels (<xref rid="pharmaceuticals-18-00235-f001" ref-type="fig">Figure 1</xref>B).</p><p>To confirm this finding, we performed correlation analyses between <italic toggle="yes">STC2</italic> and key luminal A markers, including <italic toggle="yes">ESR1</italic>, <italic toggle="yes">PGR</italic>, and <italic toggle="yes">GATA3</italic>, using the TIMER2.0 platform. As shown in <xref rid="pharmaceuticals-18-00235-f001" ref-type="fig">Figure 1</xref>C, we observed strong positive correlations, with Spearman&#x02019;s coefficients of 0.56, 0.596, and 0.554 for <italic toggle="yes">ESR1, PGR</italic>, and <italic toggle="yes">GATA3</italic>, respectively, all with highly significant <italic toggle="yes">p</italic>-values (<italic toggle="yes">p</italic> &#x0003c; 0.001).</p></sec><sec id="sec2dot2-pharmaceuticals-18-00235"><title>2.2. STC2 Is Associated with ER Regulation</title><p>To further elucidate the role of <italic toggle="yes">STC2</italic> in luminal A breast cancer, we performed gene set enrichment analysis (GSEA) on breast cancer samples from the TCGA database, focusing on cases with high <italic toggle="yes">STC2</italic> expression. This analysis showed a significant enrichment of gene sets related to ER regulation and associated pathways, indicating a strong link between <italic toggle="yes">STC2</italic> and ER-driven breast cancer. Notably, the analysis highlights enrichment in gene sets such as &#x0201c;Vantveer_Breast_cancer_ESR1_Up&#x0201d; and &#x0201c;Hallmarck_Estrogen_Response_Early&#x0201d;, suggesting that <italic toggle="yes">STC2</italic> expression is positively correlated with genes upregulated in ER-positive breast cancer and early estrogen response (<xref rid="pharmaceuticals-18-00235-f002" ref-type="fig">Figure 2</xref>). Additionally, the &#x0201c;KEGG_Persoxisome&#x0201d; pathway was also enriched, indicating a potential role of <italic toggle="yes">STC2</italic> in peroxisome-related processes linked to cellular metabolism and oxidative stress. Collectively, these findings support the hypothesis that <italic toggle="yes">STC2</italic> plays a critical role in ER-positive breast cancer by modulating estrogen signaling and peroxisome-related processes.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00235"><title>2.3. Prognostic Impact of STC2 in Breast Cancer Is Dependent on ER Status</title><p>To assess the prognostic value of <italic toggle="yes">STC2</italic> in relation to ER expression in breast cancer, survival analyses were conducted using the Kaplan&#x02013;Meier plotter platform [<xref rid="B27-pharmaceuticals-18-00235" ref-type="bibr">27</xref>]. The analyses were stratified by ER status, allowing for a comparison between ER-positive and ER-negative breast cancer patients, each of whom was followed for relapse-free survival (RFS). For the ER-positive cohort, the results indicated a significant association between high <italic toggle="yes">STC2</italic> expression and improved survival outcomes. The hazard ratio (HR) for high vs. low expression was 0.63 (95% CI: 0.56&#x02013;0.71), with a highly significant log-rank <italic toggle="yes">p</italic>-value of 3.1 &#x000d7; 10<sup>&#x02212;14</sup>. The Kaplan&#x02013;Meier survival curve shows a clear separation between the high and low <italic toggle="yes">STC2</italic> expression groups, with patients in the high-expression group demonstrating substantially better RFS across the follow-up period. (<xref rid="pharmaceuticals-18-00235-f003" ref-type="fig">Figure 3</xref>A). Conversely, in the ER-negative cohort, high <italic toggle="yes">STC2</italic> expression was associated with worse survival outcomes. The hazard ratio for high vs. low expression was 1.31 (95% CI: 1.08&#x02013;1.58), and the log-rank <italic toggle="yes">p</italic>-value was 0.0054, indicating a significant correlation. The survival curve demonstrates that patients with higher <italic toggle="yes">STC2</italic> expression had a lower probability of RFS compared to those with lower expression, suggesting that <italic toggle="yes">STC2</italic> has an adverse prognostic role in ER-negative breast cancer.</p></sec><sec sec-type="subjects" id="sec2dot4-pharmaceuticals-18-00235"><title>2.4. Differential STC2 Expression as a Predictor of Chemotherapy Response in ER-Positive and ER-Negative Breast Cancer Patients</title><p>To evaluate the relationship between <italic toggle="yes">STC2</italic> expression and its association with RFS in patients treated with chemotherapy, we used the ROC Plotter server, a database designed to identify predictive biomarkers based on gene expression using transcriptomic data from a large cohort of breast cancer patients [<xref rid="B28-pharmaceuticals-18-00235" ref-type="bibr">28</xref>]. In this analysis, we observed that within the cohort of grade II ER-positive breast cancer patients (consisting of 43 responders and 34 non-responders), <italic toggle="yes">STC2</italic> expression showed a significantly higher expression in responders, with a fold change of 1.9 between both groups (<xref rid="pharmaceuticals-18-00235-f004" ref-type="fig">Figure 4</xref>A). The Mann&#x02013;Whitney test confirmed that this difference in expression levels was statistically significant (<italic toggle="yes">p</italic> = 4.7 &#x000d7; 10<sup>&#x02212;3</sup>). The receiver operator characteristic (ROC) curve analysis yielded an area under the curve (AUC) of 0.729 (<italic toggle="yes">p</italic> = 9 &#x000d7; 10<sup>&#x02212;5</sup>), indicating an acceptable predictive value of <italic toggle="yes">STC2</italic> for chemotherapy response in this subgroup (<xref rid="pharmaceuticals-18-00235-f004" ref-type="fig">Figure 4</xref>B). The distribution of <italic toggle="yes">STC2</italic> expression across quartiles (<xref rid="pharmaceuticals-18-00235-f004" ref-type="fig">Figure 4</xref>C) further highlights a higher frequency of responders in the higher <italic toggle="yes">STC2</italic> expression quartiles, supporting the observed trend.</p><p>In the grade II ER-negative cohort, the analysis included 12 responders and 18 non-responders. In contrast to the ER-positive group, responders in the ER-negative cohort exhibited reduced expression of <italic toggle="yes">STC2</italic>, with a median expression of 154 in responders compared to 239 in non-responders (fold change of &#x02212;1.9 between both groups, <xref rid="pharmaceuticals-18-00235-f004" ref-type="fig">Figure 4</xref>D), suggesting an inverse relationship between <italic toggle="yes">STC2</italic> levels and chemotherapy response in grade II ER-negative patients. The Mann&#x02013;Whitney test showed that this reduction was statistically significant (<italic toggle="yes">p</italic>-value = 0.042). The ROC curve analysis for the ER-negative cohort yielded an AUC of 0.725, suggesting an acceptable discriminatory power (<xref rid="pharmaceuticals-18-00235-f004" ref-type="fig">Figure 4</xref>E). Additionally, the distribution of <italic toggle="yes">STC2</italic> expression across quartiles in grade II ER-negative breast cancer patients shows a contrasting pattern to that of the ER-positive cohort (<xref rid="pharmaceuticals-18-00235-f004" ref-type="fig">Figure 4</xref>F). Although the predictive value of <italic toggle="yes">STC2</italic> remains moderate, the pattern of reduced expression in responders suggests a different biological role of <italic toggle="yes">STC2</italic> in ER-negative patients compared to ER-positive cases. In grade I or III breast cancer patients, no statistically significant differences were observed between responders and non-responders in either the ER-positive or ER-negative groups.</p></sec><sec id="sec2dot5-pharmaceuticals-18-00235"><title>2.5. Dox Suppress STC2 Expression in Breast Cancer Cells</title><p>In order to evaluate the underlying mechanisms driving the differential chemotherapy response observed between ER-positive and ER-negative cohorts, we examined the effects of Dox on <italic toggle="yes">STC2</italic> expression in breast cancer cell lines. We conducted RT-qPCR experiments on the ER-positive MCF7 and ER-negative MDA-MB-231 cell lines following 24-h Dox treatment. The results revealed a significant downregulation of <italic toggle="yes">STC2</italic> mRNA expression in MCF7 cells (<xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>A), while no significant changes were observed in MDA-MB-231 cells (<xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>B).</p><p>To validate these findings, we analyzed two publicly available transcriptome datasets, GSE244574 [<xref rid="B29-pharmaceuticals-18-00235" ref-type="bibr">29</xref>] and GSE202536 [<xref rid="B30-pharmaceuticals-18-00235" ref-type="bibr">30</xref>], which examined the response to Dox treatment in MCF7 and Cal51 breast cancer cell lines, respectively. Differential expression analysis revealed significant alterations in gene expression following Dox exposure. In the GSE244574 dataset (MCF7 cells), 4302 genes were upregulated, while 4183 genes were downregulated after Dox treatment (<xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>C). Similarly, in the GSE202536 dataset (Cal51 cells), comparing untreated cells with those exposed to Dox for 24 h, 1067 genes were upregulated, and 268 genes were downregulated (<xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>D). Functional enrichment analysis of the differentially expressed genes (DEGs) indicated that in MCF7 cells, the DEGs were predominantly associated with Myc and E2F targets, oxidative phosphorylation, G2-M targets, and DNA repair (<xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>E). In contrast, the DEGs in Cal51 cells were primarily linked to the p53 pathway, TNF-alpha signaling, cholesterol homeostasis, and apoptosis (<xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>F). Regarding <italic toggle="yes">STC2</italic> expression, both datasets demonstrated a statistically significant reduction in <italic toggle="yes">STC2</italic> levels following 24 h of Dox exposure (<xref rid="app1-pharmaceuticals-18-00235" ref-type="app">Figure S4</xref>). However, the extent of downregulation varied between the two datasets. In the MCF7 cells (GSE244574 dataset, <xref rid="pharmaceuticals-18-00235-f005" ref-type="fig">Figure 5</xref>C), the downregulation of <italic toggle="yes">STC2</italic> was particularly robust, with a log2 fold change of &#x02212;3.9 (<italic toggle="yes">p</italic> adj. = 7.37 &#x000d7; 10<sup>&#x02212;18</sup>, <italic toggle="yes">p</italic>-value = 1.38 &#x000d7; 10<sup>&#x02212;20</sup>). In contrast, while the GSE202536 dataset also showed statistically significant downregulation (<italic toggle="yes">p</italic> adj. = 2.54 &#x000d7; 10<sup>&#x02212;3</sup>, <italic toggle="yes">p</italic>-value = 2.02 &#x000d7; 10<sup>&#x02212;5</sup>), the change in <italic toggle="yes">STC2</italic> expression was moderate, with a log2 fold change of &#x02212;0.62, representing a less pronounced decrease.</p><p>Finally, we analyzed <italic toggle="yes">STC2</italic> gene expression using the GSE240671 dataset [<xref rid="B31-pharmaceuticals-18-00235" ref-type="bibr">31</xref>], which contains RNA sequencing data from breast cancer patients before and after neoadjuvant chemotherapy. From the available data, we selected samples from three patients who underwent chemotherapy and had residual tumors following treatment. Our analysis showed a consistent downregulation of <italic toggle="yes">STC2</italic> gene expression in all three patients after neoadjuvant chemotherapy (<xref rid="app1-pharmaceuticals-18-00235" ref-type="app">Figure S5</xref>). The statistical analysis from the three samples confirmed these findings, revealing a log2 fold change of &#x02212;1.39 with a <italic toggle="yes">p</italic>-value of 5.29 &#x000d7; 10<sup>&#x02212;3</sup>.</p><p>Therefore, these results suggest that chemotherapy compounds lead to downregulation of <italic toggle="yes">STC2</italic> gene expression in both cellular models and clinical samples.</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-18-00235"><title>3. Discussion</title><p>In breast cancer treatment, chemotherapy remains a cornerstone of breast cancer treatment due to its effectiveness in targeting cancer cells. However, patient responses to chemotherapy are highly variable, influenced by factors such as genetic background, tumor subtype, and the presence of specific biomarkers that affect drug resistance and overall treatment outcomes [<xref rid="B32-pharmaceuticals-18-00235" ref-type="bibr">32</xref>].</p><p>This study highlights the complex regulatory mechanisms that cancer cells use to adapt to chemotherapy-induced stress, with a specific focus on STC2, a glycoprotein upregulated under various stress conditions, including hypoxia, endoplasmic reticulum stress, and nutrient deprivation, which are common in tumor microenvironment [<xref rid="B33-pharmaceuticals-18-00235" ref-type="bibr">33</xref>]. The results suggest that <italic toggle="yes">STC2</italic> is significantly overexpressed in breast cancer, especially in the luminal A subtype. This overexpression is closely linked to genetic alterations, such as gene amplifications and copy number gains, and it is associated with hormone receptor signaling pathways that are characteristic of luminal A tumors. Amplification of regions encoding <italic toggle="yes">STC2</italic> and its regulatory elements may drive its upregulation, suggesting a genetic basis for its elevated expression. Given its connection to hormone receptor signaling, <italic toggle="yes">STC2</italic> appears to play a pivotal role within ER pathways, which are central to the development and progression of luminal A tumors.</p><p>Since <italic toggle="yes">STC2</italic> is associated with ER signaling pathway as well as previous studies identifying <italic toggle="yes">STC2</italic> as a potential predictive marker for survival [<xref rid="B34-pharmaceuticals-18-00235" ref-type="bibr">34</xref>], we further analyzed its impact on RFS in breast cancer patients stratified by ER status. Using data from GEO and TCGA, we employed the Kaplan&#x02013;Meier plotter, which revealed that <italic toggle="yes">STC2</italic> prognostic significance in breast cancer is dependent on ER status: The results showed that high <italic toggle="yes">STC2</italic> expression was associated with favorable outcomes in ER-positive cases but was linked to poorer prognosis in ER-negative cases. This differential prognostic impact of <italic toggle="yes">STC2</italic> expression in breast cancers could be explained by its interaction with ER-mediated signaling pathways. In ER-positive tumors, high <italic toggle="yes">STC2</italic> expression may enhance hormone receptor signaling, promoting cell differentiation and growth in a more regulated, less aggressive manner, therefore leading to improved treatment responses and favorable outcomes. Conversely, in ER-negative tumors, high <italic toggle="yes">STC2</italic> expression may activate alternative stress-response pathways, such as those related to hypoxia, nutrient deprivation, or endoplasmic reticulum stress, which could contribute to a more aggressive tumor phenotype and poorer prognosis.</p><p>In addition to these results, we demonstrated that <italic toggle="yes">STC2</italic> expression serves as a potential predictive marker for chemotherapy response in both ER-positive and ER-negative grade II breast cancer patients, but with different outcomes: In grade II ER-positive patients, higher <italic toggle="yes">STC2</italic> expression correlates with better chemotherapy response. In grade II ER-negative patients, higher <italic toggle="yes">STC2</italic> expression is associated with an unfavorable response to chemotherapy. The context-dependent role of <italic toggle="yes">STC2</italic> in breast cancer could explain its differential predictive value for chemotherapy response. In ER-positive tumors, high <italic toggle="yes">STC2</italic> expression likely interacts with ER-mediated pathways, reinforcing a more regulated and organized response to chemotherapeutic stress. This interaction may facilitate tumor cell susceptibility to chemotherapy by promoting apoptotic pathways or enhancing DNA damage response mechanisms specific to ER-positive cells, therefore leading to a better treatment outcome. In ER-negative tumors, however, <italic toggle="yes">STC2</italic> likely shifts to activating alternative stress-response mechanisms, such as those related to cellular adaptation to hypoxia, nutrient deprivation, or endoplasmic reticulum stress. These mechanisms could enable cancer cells to survive under the harsh conditions imposed by chemotherapy, contributing to chemoresistance. In this context, <italic toggle="yes">STC2</italic> overexpression may support cell survival by upregulating pathways that protect the tumor from the cytotoxic effects of treatment, leading to a poor chemotherapy response.</p><p>While anticancer therapies often induce a wide array of stress-related proteins, including heat shock proteins, RNA chaperones, and endoplasmic reticulum-associated stress proteins [<xref rid="B35-pharmaceuticals-18-00235" ref-type="bibr">35</xref>], our findings revealed downregulation of <italic toggle="yes">STC2</italic> in response to Dox treatment. This is contrary to the typical stress response, where stress-responsive genes are often upregulated, suggesting that <italic toggle="yes">STC2</italic> may be regulated by multiple cellular pathways activated by oxidative stress. It is well-documented that oxidative stress can repress gene expression even at non-cytotoxic levels, which may explain the observed downregulation of <italic toggle="yes">STC2</italic> [<xref rid="B36-pharmaceuticals-18-00235" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-18-00235" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-18-00235" ref-type="bibr">38</xref>]. In fact, in other models have been demonstrated that oxidative stress induces a downregulation of <italic toggle="yes">STC2</italic> [<xref rid="B39-pharmaceuticals-18-00235" ref-type="bibr">39</xref>].</p><p>On the other hand, Dox treatment is known to interfere with the activity of key transcription factors involved in various cellular processes [<xref rid="B40-pharmaceuticals-18-00235" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-18-00235" ref-type="bibr">41</xref>]. This interference can occur through alterations in intracellular signaling pathways or direct post-translational modifications of transcription factors, reducing their capacity to promote gene expression. Furthermore, oxidative stress induced by Dox can impair ER function, altering the expression of ER-regulated genes [<xref rid="B42-pharmaceuticals-18-00235" ref-type="bibr">42</xref>]. Given that our data and previous reports suggest <italic toggle="yes">STC2</italic> is an estrogen-regulated protein [<xref rid="B43-pharmaceuticals-18-00235" ref-type="bibr">43</xref>], it is plausible that Dox disrupts the ER signaling pathways that typically drive <italic toggle="yes">STC2</italic> overexpression in cancer cells, leading to the downregulation of estrogen-responsive genes, including <italic toggle="yes">STC2</italic>.</p><p>The significant suppression of <italic toggle="yes">STC2</italic> expression following Dox treatment suggests that the drug may counteract the protective effects of <italic toggle="yes">STC2</italic>, therefore sensitizing cancer cells to apoptosis. This downregulation of <italic toggle="yes">STC2</italic> supports the hypothesis that <italic toggle="yes">STC2</italic> may contribute to chemoresistance in cancer therapy [<xref rid="B44-pharmaceuticals-18-00235" ref-type="bibr">44</xref>]. However, it is important to recognize that the datasets used in these analyses are not directly comparable due to several factors. For instance, the datasets were generated using distinct microarray platforms (Agilent and Affymetrix arrays), which can introduce variability in gene detection sensitivity, specificity, and expression quantification. Furthermore, differences in experimental conditions, sample handling, and platform-specific biases can lead to batch effects. Notably, the Dox concentrations varied between experiments, precluding a direct comparison of results. However, despite these limitations, the consistent observation of <italic toggle="yes">STC2</italic> downregulation upon Dox treatment across independent studies underscores the robustness of these findings and suggests a critical role for <italic toggle="yes">STC2</italic> in modulating the chemotherapeutic response. This warrants further investigation into <italic toggle="yes">STC2</italic> as a potential therapeutic target for overcoming chemoresistance.</p><p>The identification of <italic toggle="yes">STC2</italic> as a potential biomarker for predicting chemotherapy response has significant implications for breast cancer treatment. The ability to predict which patients are likely to respond to chemotherapy could guide personalized treatment strategies, potentially improving outcomes for those at risk of chemoresistance. Specifically, the stronger predictive value of <italic toggle="yes">STC2</italic> in ER-positive patients suggests that targeting <italic toggle="yes">STC2</italic> could be particularly beneficial in this subgroup.</p><p>Future studies should aim to validate these findings in larger and more diverse patient cohorts to confirm the utility of <italic toggle="yes">STC2</italic> as a biomarker for chemotherapy response. Additionally, mechanistic studies are needed to elucidate the molecular pathways through which <italic toggle="yes">STC2</italic> contributes to chemoresistance, particularly in the context of ER signaling and stress-response pathways. Understanding these mechanisms could provide insights into how <italic toggle="yes">STC2</italic> inhibitors might be developed and integrated into breast cancer treatment regimens. Furthermore, investigating the role of <italic toggle="yes">STC2</italic> in other subtypes of breast cancer, including triple-negative and HER2-positive cancers, could determine whether the findings are broadly applicable across breast cancer subtypes or specific to luminal A and ER-positive patients.</p></sec><sec id="sec4-pharmaceuticals-18-00235"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-18-00235"><title>4.1. Cell Culture</title><p>Human breast cancer cell lines MCF7 (#C0006008) and MDA-MB-231 (#C0006002) were obtained from Addexbio (San Diego, CA, USA). MCF7 cells were cultured in Dulbecco&#x02019;s Modified Eagle&#x02019;s Medium (DMEM) (Gibco, Carlsbad, CA, USA) with the addition of 10 &#x000b5;g/mL insulin (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and 10% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) fetal bovine serum (FBS) (Hyclone, Fremont, CA, USA). The MDA-MB-231 cells were grown in high-glucose DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) FBS (Hyclone, Fremont, CA, USA). All cell lines were cultured at 37 &#x000b0;C in a humidified cell incubator with 5% CO<sub>2</sub>.</p></sec><sec id="sec4dot2-pharmaceuticals-18-00235"><title>4.2. Real-Time Quantitative Reverse Transcription PCR (RT-qPCR)</title><p>Total RNA was extracted from the cultured cells using TRIzol Reagent (Invitrogen, Waltham, MA, USA), following the manufacturer&#x02019;s instructions. Briefly, cells were lysed directly in TRIzol, and the homogenate was subjected to phase separation with chloroform (Merck, Darmstadt, Germany). The aqueous phase containing RNA was carefully transferred, and RNA was precipitated with isopropanol (Merck, Darmstadt, Germany). The RNA pellet was washed with 75% ethanol, briefly air-dried, and resuspended in RNase-free water. RNA concentrations were measured using the Qubit RNA BR assay kit and the Qubit 4 fluorometer (Thermo Fisher, Waltham, MA, USA). cDNA was synthesized from 1 &#x000b5;g of total RNA using the AffinityScript qPCR cDNA Synthesis Kit (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer&#x02019;s protocol. The cDNA synthesis reaction was carried out in a 20 &#x000b5;L reaction volume, containing 10 &#x000b5;L of 2&#x000d7; master mix, 0.1 &#x000b5;g/&#x000b5;L of Oligo dT, and 1 &#x000b5;L of AffinityScript RT/RNase Block enzyme mix, and incubated at 37 &#x000b0;C for 30 min. For RT-qPCR, reactions were set up in a final volume of 25 &#x000b5;L, including 12.5 &#x000b5;L of Brilliant II SYBR Green q-RT-PCR 1-Step Master Mix (Agilent Technologies, Inc., Santa Clara, CA, USA), 0.5 &#x000b5;L of each primer (400 nM), 10.5 &#x000b5;L of nuclease-free water, and 1 &#x000b5;L of cDNA template. The primers used were: <italic toggle="yes">&#x003b2;-actin</italic> forward: TGCCGACAGGATGCAGAAG, <italic toggle="yes">&#x003b2;-actin</italic> reverse: GCCGATCCACACGGAGTACT; <italic toggle="yes">STC2</italic> forward: TCTTGTGAGATTCGGGGCTT, <italic toggle="yes">STC2</italic> reverse: ACAGGTCGTGCTTGAGGTAG. The <italic toggle="yes">STC2</italic> sequences were obtained from Huang et al. (2021) [<xref rid="B45-pharmaceuticals-18-00235" ref-type="bibr">45</xref>]. RT-qPCR was conducted on a CFX-96 real-time system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) under the following cycling conditions: 94 &#x000b0;C for 30 s, 60 &#x000b0;C for 20 s, and 72 &#x000b0;C for 20 s, repeated for 40 cycles. All RT-qPCR assays were performed in triplicate, and &#x003b2;-actin was used as a reference gene for normalization. The relative expression levels were calculated using the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method.</p></sec><sec id="sec4dot3-pharmaceuticals-18-00235"><title>4.3. Database Analysis</title><p>In this study, <italic toggle="yes">STC2</italic> mRNA expression in several cancers and corresponding normal tissues was examined using GEPIA2.0 plattform (<uri xlink:href="http://gepia.cancer-pku.cn/">http://gepia.cancer-pku.cn/</uri>; accessed on 10 July 2024) [<xref rid="B46-pharmaceuticals-18-00235" ref-type="bibr">46</xref>] and TNM web server (<uri xlink:href="https://tnmplot.com/analysis/">https://tnmplot.com/analysis/</uri>; accessed on 14 July 2024) [<xref rid="B47-pharmaceuticals-18-00235" ref-type="bibr">47</xref>]. Correlation analyses were conducted using the TIMER2.0 web server. (<uri xlink:href="http://timer.cistrome.org/">http://timer.cistrome.org/</uri>; accessed on 25 July 2024) [<xref rid="B48-pharmaceuticals-18-00235" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-18-00235" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-18-00235" ref-type="bibr">50</xref>]. These platforms facilitate the gene expression quantification using tumor and normal samples from TCGA and the GTEx databases. </p></sec><sec id="sec4dot4-pharmaceuticals-18-00235"><title>4.4. Datasets</title><p>The GEO database contains a vast repository of sequencing and microarray data contributed by research institutions worldwide. For this study, we searched datasets related to breast cancer and Dox exposure using the keywords &#x0201c;Breast cancer&#x0201d;, &#x0201c;Dox&#x0201d;, and &#x0201c;Chemotherapy&#x0201d;. This search resulted in the identification of the datasets GSE244574, GSE202536 and GSE240671. The GSE244574 dataset, published on 27 March 2024, by Naso et al. [<xref rid="B29-pharmaceuticals-18-00235" ref-type="bibr">29</xref>], provides transcriptomic data from Dox-treated MCF7 breast cancer cells and was generated using the Agilent-072363 SurePrint G3 Human GE v3 8x60K Microarray platform (039494). The GSE202536 dataset, published on 27 February 2023, by Kumar et al. [<xref rid="B30-pharmaceuticals-18-00235" ref-type="bibr">30</xref>], utilized the [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) in order to evaluate the differences between long-term resistance and short-term stress responses in triple-negative breast cancer cells. Specifically, in this database, we selected the data from Cal51 cells untreated and exposed to Dox for 24 h. Finally, we utilized the dataset GSE240671, published on 28 February 2024, by Derouane et al. [<xref rid="B31-pharmaceuticals-18-00235" ref-type="bibr">31</xref>]. This dataset, generated using the Illumina NovaSeq 6000 platform (GPL24676), includes RNA sequencing data from human mammary tumors collected from patients both before and after neoadjuvant chemotherapy. From the available data, we selected samples from three patients (R08, R13, and P56) who underwent neoadjuvant chemotherapy and had residual tumors after treatment. The inclusion criteria for this analysis were female patients aged 38 to 57 years at diagnosis, with breast cancer subtypes classified as either luminal B or triple-negative breast cancer (TNBC). All selected patients exhibited moderate or minimal residual disease post-treatment, and their molecular subtypes remained consistent both before and after chemotherapy.</p></sec><sec id="sec4dot5-pharmaceuticals-18-00235"><title>4.5. Identification of DEGs</title><p>DEGs were identified using Python (v3.12.5) within a Jupyter Notebook environment. Key libraries employed in the analysis included GSEApy (v1.1.3) for gene set enrichment analysis. Standard libraries such as matplotlib (v3.9.2) were used for plotting, pandas (v2.2.2) for data manipulation, and numpy (v2.1.1) for numerical computations. DEGs were defined as genes with adjusted <italic toggle="yes">p</italic>-values less than 0.05 and |logFC| &#x0003e; 1. Volcano plots were generated using matplotlib to visualize the DEGs.</p></sec><sec id="sec4dot6-pharmaceuticals-18-00235"><title>4.6. Functional Enrichment Analysis of DEGs</title><p>Functional annotation of DEGs was conducted using the GSEApy Python package, which supports GSEA and acts as a wrapper for Enrichr. This package enables easy enrichment analysis for Gene Ontology (GO) and KEGG pathways, producing high-quality figures. Lists of differentially expressed genes were provided for pathway enrichment, leveraging the statistical methods in GSEApy to identify significant biological processes and pathways. Additionally, GSEA analyses were performed using the GENI web server (<uri xlink:href="https://www.shaullab.com/geni">https://www.shaullab.com/geni</uri>; accessed on 18 August 2024) from breast invasive carcinoma (TCGA, PanCancer Atlas) [<xref rid="B51-pharmaceuticals-18-00235" ref-type="bibr">51</xref>].</p></sec><sec id="sec4dot7-pharmaceuticals-18-00235"><title>4.7. Survival Data Analysis</title><p>Survival data were analyzed using the Kaplan&#x02013;Meier Plotter [<xref rid="B27-pharmaceuticals-18-00235" ref-type="bibr">27</xref>], focusing on RFS in breast cancer patients. Patients were divided into low and high <italic toggle="yes">STC2</italic> expression groups based on a 50% cutoff for both expression levels. Two separate analyses were performed: one for ER-positive and another for ER-negative breast cancer patients. The ER-positive cohort included 1372 patients (Affy ID: 203438_at), while the ER-negative cohort comprised 243 patients. Quality control steps, such as excluding redundant samples and removing biased arrays, were implemented to ensure the integrity of the data. Survival differences between the low and high <italic toggle="yes">STC2</italic> expression groups were assessed using the log-rank test, and hazard ratios (HR) with corresponding confidence intervals were calculated to quantify the risk. Additionally, ROC analyses were conducted using ROC Plotter [<xref rid="B28-pharmaceuticals-18-00235" ref-type="bibr">28</xref>] to evaluate the predictive value of <italic toggle="yes">STC2</italic> expression in chemotherapy-treated subgroups. The analyses were performed separately for ER-positive and ER-negative breast cancer patients, with responses based on 5-year RFS and grade II tumors. The predictive performance of <italic toggle="yes">STC2</italic> was determined by plotting ROC curves, and AUC values were calculated. The statistical significance of the differences between responders and non-responders was assessed using the Mann&#x02013;Whitney U test.</p></sec><sec id="sec4dot8-pharmaceuticals-18-00235"><title>4.8. Statistical Analysis</title><p>Statistical analyses were conducted using GraphPad Prism version 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). The comparison of <italic toggle="yes">STC2</italic> expression between tumor and normal tissues was performed using Student&#x02019;s <italic toggle="yes">t</italic>-test. Correlations between <italic toggle="yes">STC2</italic> expression and patient survival were analyzed using Spearman&#x02019;s rank correlation test, a non-parametric approach suitable for assessing relationships between non-normally distributed variables. Kaplan&#x02013;Meier survival curves were statistically analyzed using the log-rank test, which is appropriate for comparing survival outcomes between two groups. Statistical significance was set at <italic toggle="yes">p</italic> &#x0003c; 0.05, with thresholds for significance noted as * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-18-00235"><title>5. Conclusions</title><p>This study demonstrates that <italic toggle="yes">STC2</italic> plays a significant role in the progression of ER-positive breast cancer and may serve as a reliable marker for predicting both survival outcomes and positive responses to chemotherapy, particularly in grade II ER-positive breast cancer patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank the National Agency for Research and Development (ANID) and Universidad de Tarapac&#x000e1; (UTA) for their support through research grants that facilitated this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00235"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020235/s1">https://www.mdpi.com/article/10.3390/ph18020235/s1</uri>, Figure S1: <italic toggle="yes">STC2</italic> expression across various cancer types compared to normal tissues; Figure S2: Bar graph showing the percentage of tumors with <italic toggle="yes">STC2</italic> expression higher than different cut-offs in normal tissues, along with specificity data; Figure S3: <italic toggle="yes">STC2</italic> mRNA expression and genetic alterations across various cancer types from the TCGA Pan-Cancer Atlas; Figure S4: <italic toggle="yes">STC2</italic> expression levels in breast cancer cell lines treated with Dox compared to control groups across three datasets; Figure S5: <italic toggle="yes">STC2</italic> gene expression levels before and after neoadjuvant chemotherapy in breast cancer patients.</p><supplementary-material id="pharmaceuticals-18-00235-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00235-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.P.M.; methodology, J.P.M.; software, J.P.M. and N.L.-H.; validation, J.P.M.; formal analysis, J.P.M. and N.L.-H.; investigation, J.P.M.; resources, J.P.M.; data curation, J.P.M. and N.L.-H.; writing&#x02014;original draft preparation, J.P.M.; writing&#x02014;review and editing, J.P.M.; visualization, N.L.-H.; supervision, J.P.M.; project administration, J.P.M.; funding acquisition, J.P.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data supporting the findings of this study are publicly available. The transcriptomic data analyzed in this study were obtained from the GEO under the following accession numbers: GSE244574 [<xref rid="B29-pharmaceuticals-18-00235" ref-type="bibr">29</xref>], GSE202536 [<xref rid="B30-pharmaceuticals-18-00235" ref-type="bibr">30</xref>] and GSE GSE240671 [<xref rid="B31-pharmaceuticals-18-00235" ref-type="bibr">31</xref>]. These datasets provide information on breast cancer cell lines treated with Dox and other chemotherapeutic agents. All datasets can be accessed through the GEO database (<uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</uri>; accessed on 15 August 2024).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00235"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qie</surname><given-names>S.</given-names></name>
<name><surname>Sang</surname><given-names>N.</given-names></name>
</person-group><article-title>Stanniocalcin 2 (<italic toggle="yes">STC2</italic>): A universal tumour biomarker and a potential therapeutical target</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2022</year><volume>41</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.1186/s13046-022-02370-w</pub-id><pub-id pub-id-type="pmid">35501821</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00235"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joshi</surname><given-names>A.D.</given-names></name>
</person-group><article-title>New Insights Into Physiological and Pathophysiological Functions of Stanniocalcin 2</article-title><source>Front. Endocrinol.</source><year>2020</year><volume>11</volume><elocation-id>172</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2020.00172</pub-id><pub-id pub-id-type="pmid">32296395</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00235"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeiger</surname><given-names>W.</given-names></name>
<name><surname>Ito</surname><given-names>D.</given-names></name>
<name><surname>Swetlik</surname><given-names>C.</given-names></name>
<name><surname>Oh-hora</surname><given-names>M.</given-names></name>
<name><surname>Villereal</surname><given-names>M.L.</given-names></name>
<name><surname>Thinakaran</surname><given-names>G.</given-names></name>
</person-group><article-title>Stanniocalcin 2 is a negative modulator of store-operated calcium entry</article-title><source>Mol. Cell Biol.</source><year>2011</year><volume>31</volume><fpage>3710</fpage><lpage>3722</lpage><pub-id pub-id-type="doi">10.1128/MCB.05140-11</pub-id><pub-id pub-id-type="pmid">21746875</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00235"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Jiao</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Stanniocalcin 2 Ameliorates Hepatosteatosis Through Activation of STAT3 Signaling</article-title><source>Front. Physiol.</source><year>2018</year><volume>9</volume><elocation-id>873</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00873</pub-id><pub-id pub-id-type="pmid">30038584</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00235"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joshi</surname><given-names>A.D.</given-names></name>
<name><surname>Carter</surname><given-names>D.E.</given-names></name>
<name><surname>Harper</surname><given-names>T.A.</given-names><suffix>Jr.</suffix></name>
<name><surname>Elferink</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Aryl hydrocarbon receptor-dependent stanniocalcin 2 induction by cinnabarinic acid provides cytoprotection against endoplasmic reticulum and oxidative stress</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2015</year><volume>353</volume><fpage>201</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1124/jpet.114.222265</pub-id><pub-id pub-id-type="pmid">25672339</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00235"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCudden</surname><given-names>C.R.</given-names></name>
<name><surname>James</surname><given-names>K.A.</given-names></name>
<name><surname>Hasilo</surname><given-names>C.</given-names></name>
<name><surname>Wagner</surname><given-names>G.F.</given-names></name>
</person-group><article-title>Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>45249</fpage><lpage>45258</lpage><pub-id pub-id-type="doi">10.1074/jbc.M205954200</pub-id><pub-id pub-id-type="pmid">12223480</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00235"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ito</surname><given-names>D.</given-names></name>
<name><surname>Walker</surname><given-names>J.R.</given-names></name>
<name><surname>Thompson</surname><given-names>C.S.</given-names></name>
<name><surname>Moroz</surname><given-names>I.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
<name><surname>Veselits</surname><given-names>M.L.</given-names></name>
<name><surname>Hakim</surname><given-names>A.M.</given-names></name>
<name><surname>Fienberg</surname><given-names>A.A.</given-names></name>
<name><surname>Thinakaran</surname><given-names>G.</given-names></name>
</person-group><article-title>Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties</article-title><source>Mol. Cell. Biol.</source><year>2004</year><volume>24</volume><fpage>9456</fpage><lpage>9469</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.21.9456-9469.2004</pub-id><pub-id pub-id-type="pmid">15485913</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00235"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Law</surname><given-names>A.Y.</given-names></name>
<name><surname>Wong</surname><given-names>C.K.</given-names></name>
</person-group><article-title>Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways</article-title><source>Mol. Cell. Endocrinol.</source><year>2013</year><volume>374</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2013.04.024</pub-id><pub-id pub-id-type="pmid">23664860</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00235"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Meng</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0122179</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0122179</pub-id><pub-id pub-id-type="pmid">25830567</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00235"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kita</surname><given-names>Y.</given-names></name>
<name><surname>Mimori</surname><given-names>K.</given-names></name>
<name><surname>Iwatsuki</surname><given-names>M.</given-names></name>
<name><surname>Yokobori</surname><given-names>T.</given-names></name>
<name><surname>Ieta</surname><given-names>K.</given-names></name>
<name><surname>Tanaka</surname><given-names>F.</given-names></name>
<name><surname>Ishii</surname><given-names>H.</given-names></name>
<name><surname>Okumura</surname><given-names>H.</given-names></name>
<name><surname>Natsugoe</surname><given-names>S.</given-names></name>
<name><surname>Mori</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">STC2</italic>: A predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma</article-title><source>Ann. Surg. Oncol.</source><year>2011</year><volume>18</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1245/s10434-010-1271-1</pub-id><pub-id pub-id-type="pmid">20734150</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00235"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>H.A.</given-names></name>
<name><surname>T&#x000f6;lle</surname><given-names>A.</given-names></name>
<name><surname>Jung</surname><given-names>M.</given-names></name>
<name><surname>Fritzsche</surname><given-names>F.R.</given-names></name>
<name><surname>Haendler</surname><given-names>B.</given-names></name>
<name><surname>Kristiansen</surname><given-names>I.</given-names></name>
<name><surname>Gaspert</surname><given-names>A.</given-names></name>
<name><surname>Johannsen</surname><given-names>M.</given-names></name>
<name><surname>Jung</surname><given-names>K.</given-names></name>
<name><surname>Kristiansen</surname><given-names>G.</given-names></name>
</person-group><article-title>Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma</article-title><source>Eur. Urol.</source><year>2009</year><volume>55</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2008.04.001</pub-id><pub-id pub-id-type="pmid">18450365</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00235"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>K.</given-names></name>
<name><surname>Furihata</surname><given-names>M.</given-names></name>
<name><surname>Chung</surname><given-names>S.Y.</given-names></name>
<name><surname>Uemura</surname><given-names>M.</given-names></name>
<name><surname>Yoshioka</surname><given-names>H.</given-names></name>
<name><surname>Iiyama</surname><given-names>T.</given-names></name>
<name><surname>Ashida</surname><given-names>S.</given-names></name>
<name><surname>Nasu</surname><given-names>Y.</given-names></name>
<name><surname>Fujioka</surname><given-names>T.</given-names></name>
<name><surname>Shuin</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer</article-title><source>Cancer Sci.</source><year>2009</year><volume>100</volume><fpage>914</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01117.x</pub-id><pub-id pub-id-type="pmid">19298603</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00235"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Volland</surname><given-names>S.</given-names></name>
<name><surname>Kugler</surname><given-names>W.</given-names></name>
<name><surname>Schweigerer</surname><given-names>L.</given-names></name>
<name><surname>Wilting</surname><given-names>J.</given-names></name>
<name><surname>Becker</surname><given-names>J.</given-names></name>
</person-group><article-title>Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma</article-title><source>Int. J. Cancer</source><year>2009</year><volume>125</volume><fpage>2049</fpage><lpage>2057</lpage><pub-id pub-id-type="doi">10.1002/ijc.24564</pub-id><pub-id pub-id-type="pmid">19582875</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00235"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
<name><surname>Su</surname><given-names>F.</given-names></name>
<name><surname>Shu</surname><given-names>X.</given-names></name>
<name><surname>Xie</surname><given-names>W.</given-names></name>
<name><surname>Feng</surname><given-names>M.</given-names></name>
<name><surname>Xiong</surname><given-names>B.</given-names></name>
</person-group><article-title>Upregulation of <italic toggle="yes">STC2</italic> in colorectal cancer and its clinicopathological significance</article-title><source>OncoTargets Ther.</source><year>2019</year><volume>12</volume><fpage>1249</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.2147/OTT.S191609</pub-id><pub-id pub-id-type="pmid">30863092</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00235"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouras</surname><given-names>T.</given-names></name>
<name><surname>Southey</surname><given-names>M.C.</given-names></name>
<name><surname>Chang</surname><given-names>A.C.</given-names></name>
<name><surname>Reddel</surname><given-names>R.R.</given-names></name>
<name><surname>Willhite</surname><given-names>D.</given-names></name>
<name><surname>Glynne</surname><given-names>R.</given-names></name>
<name><surname>Henderson</surname><given-names>M.A.</given-names></name>
<name><surname>Armes</surname><given-names>J.E.</given-names></name>
<name><surname>Venter</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer</article-title><source>Cancer Res.</source><year>2002</year><volume>62</volume><fpage>1289</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">11888893</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00235"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makhlouf</surname><given-names>S.</given-names></name>
<name><surname>Althobiti</surname><given-names>M.</given-names></name>
<name><surname>Toss</surname><given-names>M.</given-names></name>
<name><surname>Muftah</surname><given-names>A.A.</given-names></name>
<name><surname>Mongan</surname><given-names>N.P.</given-names></name>
<name><surname>Lee</surname><given-names>A.H.S.</given-names></name>
<name><surname>Green</surname><given-names>A.R.</given-names></name>
<name><surname>Rakha</surname><given-names>E.A.</given-names></name>
</person-group><article-title>The Clinical and Biological Significance of Estrogen Receptor-Low Positive Breast Cancer</article-title><source>Mod. Pathol.</source><year>2023</year><volume>36</volume><fpage>100284</fpage><pub-id pub-id-type="doi">10.1016/j.modpat.2023.100284</pub-id><pub-id pub-id-type="pmid">37474005</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00235"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamura</surname><given-names>J.</given-names></name>
<name><surname>Miyoshi</surname><given-names>Y.</given-names></name>
<name><surname>Tamaki</surname><given-names>Y.</given-names></name>
<name><surname>Taguchi</surname><given-names>T.</given-names></name>
<name><surname>Iwao</surname><given-names>K.</given-names></name>
<name><surname>Monden</surname><given-names>M.</given-names></name>
<name><surname>Kato</surname><given-names>K.</given-names></name>
<name><surname>Noguchi</surname><given-names>S.</given-names></name>
</person-group><article-title>mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers</article-title><source>Cancer Sci.</source><year>2004</year><volume>95</volume><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb02198.x</pub-id><pub-id pub-id-type="pmid">15546506</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00235"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>R.</given-names></name>
<name><surname>Yao</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>R.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Ou</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>C.</given-names></name>
</person-group><article-title><italic toggle="yes">STC2</italic> suppresses triple-negative breast cancer migration and invasion by inhibition on EMT and promotion on cell apoptosis</article-title><source>Discov. Oncol.</source><year>2024</year><volume>15</volume><fpage>339</fpage><pub-id pub-id-type="doi">10.1007/s12672-024-01196-6</pub-id><pub-id pub-id-type="pmid">39117970</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00235"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luque-Bolivar</surname><given-names>A.</given-names></name>
<name><surname>P&#x000e9;rez-Mora</surname><given-names>E.</given-names></name>
<name><surname>Villegas</surname><given-names>V.E.</given-names></name>
<name><surname>Rond&#x000f3;n-Lagos</surname><given-names>M.</given-names></name>
</person-group><article-title>Resistance and Overcoming Resistance in Breast Cancer</article-title><source>Breast Cancer Targets Ther.</source><year>2020</year><volume>12</volume><fpage>211</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.2147/BCTT.S270799</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-18-00235"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Sarkar</surname><given-names>S.</given-names></name>
<name><surname>Scott</surname><given-names>L.</given-names></name>
<name><surname>Danelisen</surname><given-names>I.</given-names></name>
<name><surname>Trush</surname><given-names>M.A.</given-names></name>
<name><surname>Jia</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Y.R.</given-names></name>
</person-group><article-title>Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress</article-title><source>React. Oxyg. Species</source><year>2016</year><volume>1</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.20455/ros.2016.835</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-18-00235"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kciuk</surname><given-names>M.</given-names></name>
<name><surname>Gieleci&#x00144;ska</surname><given-names>A.</given-names></name>
<name><surname>Mujwar</surname><given-names>S.</given-names></name>
<name><surname>Ko&#x00142;at</surname><given-names>D.</given-names></name>
<name><surname>Ka&#x00142;uzi&#x00144;ska-Ko&#x00142;at</surname><given-names>&#x0017b;.</given-names></name>
<name><surname>Celik</surname><given-names>I.</given-names></name>
<name><surname>Kontek</surname><given-names>R.</given-names></name>
</person-group><article-title>Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>659</elocation-id><pub-id pub-id-type="doi">10.3390/cells12040659</pub-id><pub-id pub-id-type="pmid">36831326</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00235"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paskeh</surname><given-names>M.D.A.</given-names></name>
<name><surname>Saebfar</surname><given-names>H.</given-names></name>
<name><surname>Mahabady</surname><given-names>M.K.</given-names></name>
<name><surname>Orouei</surname><given-names>S.</given-names></name>
<name><surname>Hushmandi</surname><given-names>K.</given-names></name>
<name><surname>Entezari</surname><given-names>M.</given-names></name>
<name><surname>Hashemi</surname><given-names>M.</given-names></name>
<name><surname>Aref</surname><given-names>A.R.</given-names></name>
<name><surname>Hamblin</surname><given-names>M.R.</given-names></name>
<name><surname>Ang</surname><given-names>H.L.</given-names></name>
<etal/>
</person-group><article-title>Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy</article-title><source>Life Sci.</source><year>2022</year><volume>298</volume><fpage>120463</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120463</pub-id><pub-id pub-id-type="pmid">35259354</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00235"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tufail</surname><given-names>M.</given-names></name>
<name><surname>Cui</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
</person-group><article-title>Breast cancer: Molecular mechanisms of underlying resistance and therapeutic approaches</article-title><source>Am. J. Cancer Res.</source><year>2022</year><volume>12</volume><fpage>2920</fpage><lpage>2949</lpage><pub-id pub-id-type="pmid">35968356</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00235"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Pan</surname><given-names>Z.</given-names></name>
</person-group><article-title>Endoplasmic reticulum stress-related features predict the prognosis of osteosarcoma and reveal <italic toggle="yes">STC2</italic> as a novel risk indicator for disease progression</article-title><source>Front. Oncol.</source><year>2024</year><volume>14</volume><elocation-id>1453173</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2024.1453173</pub-id><pub-id pub-id-type="pmid">39119088</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00235"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qie</surname><given-names>S.</given-names></name>
<name><surname>Xiong</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Sang</surname><given-names>N.</given-names></name>
</person-group><article-title>Stanniocalcin 2 governs cancer cell adaptation to nutrient insufficiency through alleviation of oxidative stress</article-title><source>Cell Death Dis.</source><year>2024</year><volume>15</volume><fpage>567</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06961-7</pub-id><pub-id pub-id-type="pmid">39107307</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00235"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiwari</surname><given-names>A.</given-names></name>
<name><surname>Trivedi</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>S.-Y.</given-names></name>
</person-group><article-title>Tumor microenvironment: Barrier or opportunity towards effective cancer therapy</article-title><source>J. Biomed. Sci.</source><year>2022</year><volume>29</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.1186/s12929-022-00866-3</pub-id><pub-id pub-id-type="pmid">36253762</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00235"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name>
</person-group><article-title>Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2021</year><volume>19</volume><fpage>4101</fpage><lpage>4109</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.07.014</pub-id><pub-id pub-id-type="pmid">34527184</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00235"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fekete</surname><given-names>J.T.</given-names></name>
<name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name>
</person-group><article-title>ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients</article-title><source>Int. J. Cancer</source><year>2019</year><volume>145</volume><fpage>3140</fpage><lpage>3151</lpage><pub-id pub-id-type="doi">10.1002/ijc.32369</pub-id><pub-id pub-id-type="pmid">31020993</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00235"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naso</surname><given-names>F.D.</given-names></name>
<name><surname>Bruqi</surname><given-names>K.</given-names></name>
<name><surname>Manzini</surname><given-names>V.</given-names></name>
<name><surname>Chiurchi&#x000f9;</surname><given-names>V.</given-names></name>
<name><surname>D&#x02019;Onofrio</surname><given-names>M.</given-names></name>
<name><surname>Arisi</surname><given-names>I.</given-names></name>
<name><surname>Strappazzon</surname><given-names>F.</given-names></name>
</person-group><article-title>miR-218-5p and doxorubicin combination enhances anticancer activity in breast cancer cells through Parkin-dependent mitophagy inhibition</article-title><source>Cell Death Discov.</source><year>2024</year><volume>10</volume><fpage>149</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-01914-7</pub-id><pub-id pub-id-type="pmid">38514650</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00235"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>U.</given-names></name>
<name><surname>Castellanos-Uribe</surname><given-names>M.</given-names></name>
<name><surname>May</surname><given-names>S.T.</given-names></name>
<name><surname>Yag&#x000fc;e</surname><given-names>E.</given-names></name>
</person-group><article-title>Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer</article-title><source>Gene</source><year>2023</year><volume>850</volume><fpage>146930</fpage><pub-id pub-id-type="doi">10.1016/j.gene.2022.146930</pub-id><pub-id pub-id-type="pmid">36195266</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00235"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Derouane</surname><given-names>F.</given-names></name>
<name><surname>Desgres</surname><given-names>M.</given-names></name>
<name><surname>Moroni</surname><given-names>C.</given-names></name>
<name><surname>Ambroise</surname><given-names>J.</given-names></name>
<name><surname>Berli&#x000e8;re</surname><given-names>M.</given-names></name>
<name><surname>Van Bockstal</surname><given-names>M.R.</given-names></name>
<name><surname>Galant</surname><given-names>C.</given-names></name>
<name><surname>van Marcke</surname><given-names>C.</given-names></name>
<name><surname>Vara-Messler</surname><given-names>M.</given-names></name>
<name><surname>Hutten</surname><given-names>S.J.</given-names></name>
<etal/>
</person-group><article-title>Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers</article-title><source>Breast Cancer Res.</source><year>2024</year><volume>26</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s13058-024-01788-8</pub-id><pub-id pub-id-type="pmid">38374113</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00235"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van der Zanden</surname><given-names>S.Y.</given-names></name>
<name><surname>Qiao</surname><given-names>X.</given-names></name>
<name><surname>Neefjes</surname><given-names>J.</given-names></name>
</person-group><article-title>New insights into the activities and toxicities of the old anticancer drug doxorubicin</article-title><source>FEBS J.</source><year>2021</year><volume>288</volume><fpage>6095</fpage><lpage>6111</lpage><pub-id pub-id-type="doi">10.1111/febs.15583</pub-id><pub-id pub-id-type="pmid">33022843</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00235"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>H.</given-names></name>
<name><surname>Qie</surname><given-names>S.</given-names></name>
<name><surname>Guo</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Zou</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>T.</given-names></name>
<name><surname>Su</surname><given-names>Y.</given-names></name>
<name><surname>Zong</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>He</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Stanniocalcin 2 (<italic toggle="yes">STC2</italic>) expression promotes post-radiation survival, migration and invasion of nasopharyngeal carcinoma cells</article-title><source>Cancer Manag. Res.</source><year>2019</year><volume>11</volume><fpage>6411</fpage><lpage>6424</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S197607</pub-id><pub-id pub-id-type="pmid">31372045</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00235"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esseghir</surname><given-names>S.</given-names></name>
<name><surname>Kennedy</surname><given-names>A.</given-names></name>
<name><surname>Seedhar</surname><given-names>P.</given-names></name>
<name><surname>Nerurkar</surname><given-names>A.</given-names></name>
<name><surname>Poulsom</surname><given-names>R.</given-names></name>
<name><surname>Reis-Filho</surname><given-names>J.S.</given-names></name>
<name><surname>Isacke</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>3164</fpage><lpage>3173</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0224</pub-id><pub-id pub-id-type="pmid">17545519</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00235"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yun</surname><given-names>C.W.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Lim</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>60</elocation-id><pub-id pub-id-type="doi">10.3390/cells9010060</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-18-00235"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>MOREL</surname><given-names>Y.</given-names></name>
<name><surname>BAROUKI</surname><given-names>R.</given-names></name>
</person-group><article-title>Repression of gene expression by oxidative stress</article-title><source>Biochem. J.</source><year>1999</year><volume>342</volume><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1042/bj3420481</pub-id><pub-id pub-id-type="pmid">10477257</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00235"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhargavan</surname><given-names>B.</given-names></name>
<name><surname>Chhunchha</surname><given-names>B.</given-names></name>
<name><surname>Kubo</surname><given-names>E.</given-names></name>
<name><surname>Singh</surname><given-names>D.P.</given-names></name>
</person-group><article-title>DNA methylation as an epigenetic mechanism in the regulation of LEDGF expression and biological response in aging and oxidative stress</article-title><source>Cell Death Discov.</source><year>2024</year><volume>10</volume><fpage>296</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-02076-2</pub-id><pub-id pub-id-type="pmid">38909054</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00235"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Posadino</surname><given-names>A.M.</given-names></name>
<name><surname>Phu</surname><given-names>H.T.</given-names></name>
<name><surname>Cossu</surname><given-names>A.</given-names></name>
<name><surname>Giordo</surname><given-names>R.</given-names></name>
<name><surname>Fois</surname><given-names>M.</given-names></name>
<name><surname>Thuan</surname><given-names>D.T.B.</given-names></name>
<name><surname>Piga</surname><given-names>A.</given-names></name>
<name><surname>Sotgia</surname><given-names>S.</given-names></name>
<name><surname>Zinellu</surname><given-names>A.</given-names></name>
<name><surname>Carru</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Oxidative stress-induced Akt downregulation mediates green tea toxicity towards prostate cancer cells</article-title><source>Toxicol. In Vitro</source><year>2017</year><volume>42</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2017.05.005</pub-id><pub-id pub-id-type="pmid">28495234</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00235"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>P.H.</given-names></name>
<name><surname>Na</surname><given-names>S.S.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Cho</surname><given-names>J.Y.</given-names></name>
</person-group><article-title>Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress</article-title><source>BMB Rep.</source><year>2015</year><volume>48</volume><fpage>702</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2015.48.12.158</pub-id><pub-id pub-id-type="pmid">26424558</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00235"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartlett</surname><given-names>J.J.</given-names></name>
<name><surname>Trivedi</surname><given-names>P.C.</given-names></name>
<name><surname>Yeung</surname><given-names>P.</given-names></name>
<name><surname>Kienesberger</surname><given-names>P.C.</given-names></name>
<name><surname>Pulinilkunnil</surname><given-names>T.</given-names></name>
</person-group><article-title>Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy</article-title><source>Biochem. J.</source><year>2016</year><volume>473</volume><fpage>3769</fpage><lpage>3789</lpage><pub-id pub-id-type="doi">10.1042/BCJ20160385</pub-id><pub-id pub-id-type="pmid">27487838</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00235"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>AbuHammad</surname><given-names>S.</given-names></name>
<name><surname>Zihlif</surname><given-names>M.</given-names></name>
</person-group><article-title>Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line</article-title><source>Genomics</source><year>2013</year><volume>101</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.ygeno.2012.11.009</pub-id><pub-id pub-id-type="pmid">23201559</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00235"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Lu</surname><given-names>B.</given-names></name>
<name><surname>Scott</surname><given-names>G.K.</given-names></name>
<name><surname>Chang</surname><given-names>C.H.</given-names></name>
<name><surname>Baldwin</surname><given-names>M.A.</given-names></name>
<name><surname>Benz</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer</article-title><source>Mol. Cell. Endocrinol.</source><year>1998</year><volume>146</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/S0303-7207(98)00161-0</pub-id><pub-id pub-id-type="pmid">10022773</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00235"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>S.-t.</given-names></name>
<name><surname>Wang</surname><given-names>H.-q.</given-names></name>
<name><surname>Yang</surname><given-names>T.-c.</given-names></name>
<name><surname>Wang</surname><given-names>D.-w.</given-names></name>
<name><surname>Yang</surname><given-names>L.-j.</given-names></name>
<name><surname>Xi</surname><given-names>Y.-q.</given-names></name>
<name><surname>Kong</surname><given-names>F.-z.</given-names></name>
<name><surname>Pan</surname><given-names>X.-k.</given-names></name>
<name><surname>Xu</surname><given-names>L.-h.</given-names></name>
<name><surname>Feng</surname><given-names>M.-h.</given-names></name>
<etal/>
</person-group><article-title>Expression of Stanniocalcin 2 in Breast Cancer and Its Clinical Significance</article-title><source>Curr. Med. Sci.</source><year>2019</year><volume>39</volume><fpage>978</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1007/s11596-019-2131-2</pub-id><pub-id pub-id-type="pmid">31845230</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00235"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>X.</given-names></name>
<name><surname>Zhan</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Qu</surname><given-names>C.</given-names></name>
</person-group><article-title>Research progress of <italic toggle="yes">STC2</italic> in breast cancer</article-title><source>Biophys. Rep.</source><year>2021</year><volume>7</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">37287492</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00235"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Qin</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Pu</surname><given-names>J.</given-names></name>
</person-group><article-title>SNHG17 Serves as an Oncogenic lncRNA by Regulating the miR-361-3p/<italic toggle="yes">STC2</italic> Axis in Rectal Cancer</article-title><source>Front. Genet.</source><year>2021</year><volume>12</volume><elocation-id>654686</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.654686</pub-id><pub-id pub-id-type="pmid">34249085</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00235"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Z.</given-names></name>
<name><surname>Kang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
</person-group><article-title>GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>W556</fpage><lpage>W560</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz430</pub-id><pub-id pub-id-type="pmid">31114875</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00235"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartha</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name>
</person-group><article-title>TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>2622</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22052622</pub-id><pub-id pub-id-type="pmid">33807717</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00235"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Fu</surname><given-names>J.</given-names></name>
<name><surname>Zeng</surname><given-names>Z.</given-names></name>
<name><surname>Cohen</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>X.S.</given-names></name>
</person-group><article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>W509</fpage><lpage>W514</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa407</pub-id><pub-id pub-id-type="pmid">32442275</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00235"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Traugh</surname><given-names>N.</given-names></name>
<name><surname>Chen</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>J.S.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>X.S.</given-names></name>
</person-group><article-title>TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>e108</fpage><lpage>e110</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0307</pub-id><pub-id pub-id-type="pmid">29092952</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00235"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Severson</surname><given-names>E.</given-names></name>
<name><surname>Pignon</surname><given-names>J.C.</given-names></name>
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Novak</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>P.</given-names></name>
<name><surname>Shen</surname><given-names>H.</given-names></name>
<name><surname>Aster</surname><given-names>J.C.</given-names></name>
<name><surname>Rodig</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy</article-title><source>Genome Biol.</source><year>2016</year><volume>17</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-1028-7</pub-id><pub-id pub-id-type="pmid">27549193</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00235"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayashi</surname><given-names>A.</given-names></name>
<name><surname>Ruppo</surname><given-names>S.</given-names></name>
<name><surname>Heilbrun</surname><given-names>E.E.</given-names></name>
<name><surname>Mazzoni</surname><given-names>C.</given-names></name>
<name><surname>Adar</surname><given-names>S.</given-names></name>
<name><surname>Yassour</surname><given-names>M.</given-names></name>
<name><surname>Rmaileh</surname><given-names>A.A.</given-names></name>
<name><surname>Shaul</surname><given-names>Y.D.</given-names></name>
</person-group><article-title>GENI: A web server to identify gene set enrichments in tumor samples</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2023</year><volume>21</volume><fpage>5531</fpage><lpage>5537</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2023.10.053</pub-id><pub-id pub-id-type="pmid">38034403</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00235-f001"><label>Figure 1</label><caption><p><italic toggle="yes">STC2</italic> expression analysis in breast cancer tissues compared to normal tissues. (<bold>A</bold>) Violin plot showing <italic toggle="yes">STC2</italic> gene expression levels in normal and tumor tissues. The plot includes paired tumor and adjacent normal tissues (<bold>B</bold>) Box plots showing <italic toggle="yes">STC2</italic> expression in different breast cancer subtypes. Tumor samples are shown in red; Normal samples in blue. (<bold>C</bold>) Correlation plots showing the association of <italic toggle="yes">STC2</italic> expression with luminal markers <italic toggle="yes">ESR1</italic>, <italic toggle="yes">PGR</italic>, and <italic toggle="yes">GATA3</italic>. Each plot displays the correlation coefficient (rho) and <italic toggle="yes">p</italic>-value, indicating significant positive correlations between <italic toggle="yes">STC2</italic> and the luminal markers. * <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pharmaceuticals-18-00235-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00235-f002"><label>Figure 2</label><caption><p>GSEA of <italic toggle="yes">STC2</italic> expression in breast invasive carcinoma using GENI web server. The analysis was conducted by selecting breast tissue and focusing on <italic toggle="yes">STC2</italic> from the TCGA PanCancer Atlas dataset. Predefined Curated (<bold>A</bold>), Hallmark (<bold>B</bold>), PID (<bold>C</bold>), and KEGG (<bold>D</bold>) gene sets were applied. The colors in the gradient below the enrichment curve reflect the correlation with the studied condition: the red area indicates genes positively correlated with <italic toggle="yes">STC2</italic> expression in breast invasive carcinoma, while the blue area represents genes with a negative correlation.</p></caption><graphic xlink:href="pharmaceuticals-18-00235-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00235-f003"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier survival curves showing the impact of <italic toggle="yes">STC2</italic> expression on RFS in ER-positive (<bold>A</bold>) and ER-negative (<bold>B</bold>) breast cancer patients. The curves depict the probability of RFS over time for each group, with high <italic toggle="yes">STC2</italic> expression denoted in red and low <italic toggle="yes">STC2</italic> expression in black.</p></caption><graphic xlink:href="pharmaceuticals-18-00235-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00235-f004"><label>Figure 4</label><caption><p>Expression of <italic toggle="yes">STC2</italic> and its association with chemotherapy response in grade II breast cancer patients. (<bold>A</bold>) Box plot showing <italic toggle="yes">STC2</italic> expression levels comparing non-responders and responders to chemotherapy in grade II ER-positive breast cancer patients. (<bold>B</bold>) ROC curve evaluating the diagnostic performance of <italic toggle="yes">STC2</italic> expression in ER-positive breast cancer patients. (<bold>C</bold>) Distribution of response status across quartiles of <italic toggle="yes">STC2</italic> expression in ER-positive breast cancer patients. (<bold>D</bold>) Box plot comparing <italic toggle="yes">STC2</italic> expression levels between non-responders and responders to chemotherapy in grade II ER-negative breast cancer patients. (<bold>E</bold>) ROC curve assessing the predictive value of <italic toggle="yes">STC2</italic> expression for chemotherapy response in ER-negative breast cancer patients. (<bold>F</bold>) Distribution of response status across <italic toggle="yes">STC2</italic> expression quartiles in ER-negative breast cancer patients.</p></caption><graphic xlink:href="pharmaceuticals-18-00235-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00235-f005"><label>Figure 5</label><caption><p>Dox induces a suppression of <italic toggle="yes">STC2</italic> gene expression. (<bold>A</bold>,<bold>B</bold>) RT-qPCR analysis of <italic toggle="yes">STC2</italic> gene expression in MCF7 (<bold>A</bold>) and MDA-MB-231 (<bold>B</bold>) cells exposed to Dox for 24 h. (<bold>C</bold>,<bold>D</bold>) Volcano plots of datasets GSE244574 and GSE202536 showing differentially upregulated (red) and downregulated (blue) genes, with <italic toggle="yes">STC2</italic> highlighted in a yellow dot. (<bold>E</bold>,<bold>F</bold>) Bar charts represent the top enriched pathways based on adjusted <italic toggle="yes">p</italic>-values. Data are presented as mean &#x000b1; standard error of the mean from triplicate experiments. (* <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="pharmaceuticals-18-00235-g005" position="float"/></fig></floats-group></article>